Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden

References

• Edelman MJ, Belani CP, Socinski MA, et al. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010;5:110-16
   PubMed Web of Science ®Google Scholar
• Shi AA, Digumarthy SR, Temel JS, et al. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol 2006;1:205-10
   PubMed Web of Science ®Google Scholar
• Zietemann V, Duell T. Every-day clinical practice in patients with advanced non-small-cell lung cancer. Lung Cancer 2010;68:273-7
   PubMed Web of Science ®Google Scholar
• Sorensen JB, Hansen HH, Hansen M, et al. Brain metastases in adenocarcinoma of the lung, risk groups, and prognosis. J Clin Oncol 1988;6:1474-80
   PubMed Web of Science ®Google Scholar
• Duell T, Kappler S, Knoferi B, et al. Prevalence and risk factors of brain metastases in patients with newly diagnosed advanced non-small cell lung cancer. Cancer Treat Commun 2015;4:106-12
   Google Scholar
• Han G, Bi J, Tan W, et al. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? Oncotarget 2016;7:56998-7010
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30:419-25
   PubMed Web of Science ®Google Scholar
• Ahluwalia MS, Winkler F. Targeted and immunotherapeutic approaches in brain metastases. ASCO, Chicago, IL: Educational Book, 2015. p 67-74
   Google Scholar
• Andrews RJ, Gluck DS, Konchingeri RH. Surgical resection of brain metastases from lung cancer. Acta Neurochir (Wien) 1996;138:382-9
   PubMed Web of Science ®Google Scholar
• Thomas AJ, Rock JP, Johnson CC, et al. Survival of patients with synchronous brain metastases: an epidemiological study in southeastern Michigan. J Neurosurg 2000;93:927-31
   PubMed Web of Science ®Google Scholar
• Nieder C, Norum J, Stemland JG, et al. Resource utilization in patients with brain metastases managed with best supportive care, radiotherapy and/or surgical resection: a Markov analysis. Oncology 2010;78:348-55
   PubMed Web of Science ®Google Scholar
• Ray S, Dacosta-Byfield S, Ganguli A, et al. Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer. J Neurooncol 2013;114:117-25
   PubMed Web of Science ®Google Scholar
• Schubart JR, Kinzie MB, Farace E. Caring for the brain tumor patient: family caregiver burden and unmet needs. Neuro Oncol 2008;10:61-72
   PubMed Web of Science ®Google Scholar
• Tang V, Rathbone M, Park Dorsay J, et al. Rehabilitation in primary and metastatic brain tumours: impact of functional outcomes on survival. J Neurol 2008;255:820-7
   PubMed Web of Science ®Google Scholar
• Welzel G, Fleckenstein K, Schaefer J, et al. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys 2008;72:1311-18
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Zugic A, Rankovic A, et al. Radiation therapy remains the key cost driver of oncology inpatient treatment. J Med Econ 2015;18:29-36
   PubMed Web of Science ®Google Scholar
• Peters S, Bexelius C, Munk V, et al. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev 2016;45:139-62
   PubMed Web of Science ®Google Scholar
• Roughley A, Damonte E, Taylor-Stokes G, et al. Impact of brain metastases on quality of life and estimated life expectancy in patients with advanced non-small cell lung cancer. Value Health 2014;17:A650
   PubMed Web of Science ®Google Scholar
• Sekine I, Yamamoto N, Nishio K, et al. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99:1757-62
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46
   PubMed Web of Science ®Google Scholar
• Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014;9:154-62
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011;29:2066-70
   PubMed Web of Science ®Google Scholar
• Tomasini P, Serdjebi C, Khobta N, et al. EGFR and KRAS mutations predict the incidence and outcome of brain metastases in non-small cell lung cancer. Int J Mol Sci 2016;17:pii: E2132. doi: 10.3390/ijms17122132
   PubMed Web of Science ®Google Scholar
• Stanic K, Zwitter M, Turnsek N, et al. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol 2014;48:173-83
   PubMed Web of Science ®Google Scholar
• Baek MY, Ahn HK, Park KR, et al. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Korean J Intern Med 2016 doi: 10.3904/kjim.2015.158. [Epub ahead of print]
   Google Scholar
• NCCN. National Comprehensive Cancer Network non-small cell lung cancer version 8.2017. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Fort Washington, PA: NCCN; 2017
   Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42
   PubMed Web of Science ®Google Scholar
• Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2012;18:4406-14
   PubMed Web of Science ®Google Scholar
• Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010;16:5873-82
   PubMed Web of Science ®Google Scholar
• Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005;103:2344-8
   PubMed Web of Science ®Google Scholar
• Lange A, Prenzler A, Frank M, et al. A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BMC Pulm Med 2014;14:192
   PubMed Web of Science ®Google Scholar
• Fox KM, Brooks JM, Kim J. Metastatic non-small cell lung cancer: costs associated with disease progression. Am J Manag Care 2008;14:565-71
   PubMed Web of Science ®Google Scholar
• Guerin A, Sasane M, Zhang J, et al. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ 2015;18:312-22
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Weycker D, Glass A, et al. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy. BMC Health Serv Res 2011;11:305
   PubMed Web of Science ®Google Scholar
• Duh MS, Reynolds Weiner J, Lefebvre P, et al. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. Curr Med Res Opin 2008;24:967-74
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Consumer price index. Washington, DC: United States Department of Labor; 2016
   Google Scholar
• Dagovic A, Matter Walstra K, Gutzwiller FS, et al. Resource use and costs of newly diagnosed cancer initial medical care. Eur J Oncol 2014;19:166-84
   Google Scholar
• Ali A, Goffin JR, Arnold A, et al. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol 2013;20:e300-6
   PubMed Web of Science ®Google Scholar
• Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies—report of the ISPOR Task Force on Retrospective Databases. Value Health 2003;6:90-7
   PubMed Web of Science ®Google Scholar